

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A method of treating a patient suffering from Mild Cognitive Impairment, comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.
2. (Original): A method of treating a patient suffering from neuronal damage as a result of CNS hypoxia comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.
3. (Currently Amended): A method according to claim 2, wherein said neuronal damage is the result of Coronary Artery Bypass Grafting (CABG) or ~~perinatal hypoxia~~.
4. (Original): A method according to claim 2, wherein said patient is treated for memory impairment and/or cognitive impairment due to such neuronal damage,
5. (Currently Amended): A method of treating a patient suffering from memory impairment and/or cognitive impairment due to schizophrenia, Huntington's disease, Pick's disease, Creutzfeldt-Jakob ~~Creutzfeld-Jakob~~ disease, and other neurological conditions, comprising administering to the patient an effective amount of (+)- isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.
6. (Cancelled):
7. (Cancelled):
8. (Original): A method of treating a patient suffering from suffering from conditions of memory and/or cognition impairment due to disease states selected from

attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.

9. (Original): A method of treating a patient suffering from suffering from tinnitus and/or other symptoms of cerebral insufficiency, comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.

10. (Currently Amended): A method according claim 1 to any one of claims 1-9, further comprising administering to said patient one or more [[a]] further pharmaceutical agents agent for the treatment of cognitive impairment and/or memory loss, wherein said one or more further pharmaceutical agents are agent is selected from nicotinic α -7 agonists, PDE4 inhibitors, calcium channel blockers, muscarinic m1 and m2 modulators, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, and cannabinoid modulators.

11. (Currently Amended): A method according to claim 10, wherein said one or more further pharmaceutical agents are agent is selected from amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, nitrendipine, nisoldipine, and memantine.

12. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with schizophrenia according to claim 5, further comprising administering to said patient an effective amount of one or more further pharmaceutical agents selected from Clozaril, Zyprexa, Risperidone, and/or Seroquel.

13. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with Huntington's disease according to claim 5, further comprising administering to said patient an effective amount of one or more further pharmaceutical agents selected from Amitriptyline, Imipramine, Despiramine, Nortriptyline,

Paroxetine, Fluoxetine, Sertraline, Tetrabenazine, Haloperidol, Chlorpromazine, Thioridazine, Sulpride, Quetiapine, Clozapine, and or Risperidone.

14. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with Attention Deficit Hyperactivity Disorder (ADHD) according to claim 8, further comprising administering to said patient an effective amount of one or more further pharmaceutical agents selected from Ritalin, Dexedrine, Dextrostat, Cylert, and or Adderall.

15. (Cancelled):

16. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with Alzheimer's disease comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Akatinol, Neotropin, Eldepryl, Estrogen, and or Clioquinol.

17. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with Parkinson's disease comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Levodopa, Parlodel, Permax, Mirapex, Tasmar, Comtan, Kemadrin, Artane, and or Cogentin.

18. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with depression comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Prozac, Zoloft, Paxil, Reboxetine, Wellbutrin, Olanzapine, Fluoxetine, Elavil, Tofranil, Pamelor, Nardil, Parnate, Desyrel, Effexor, Desyrel,

Vivactil, Sinequan, Parnate, Zyprexa, Tryptanol, Serzone, Risperidal, Haldol, Faverin, Seroxat, Remeron, or Nortrilene

19. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with dementia comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Thioridazine, Haloperidal, and/or Risperidone.

20. (Cancelled):

21. (Currently Amended): A method of treating a patient suffering from memory and/or cognitive impairment associated with bipolar disorder comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more additional pharmaceutical agents selected from Lithium, Zyprexa, Depakote, and Zyprexa.

22. (Currently Amended): A method according to claim 1 ~~any one of claims 1-21~~, wherein said patient is human.

23. (New): A pharmaceutical composition comprising (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and one or more additional pharmaceutical agents selected from Lithium, Depakote, and Zyprexa.

24. (New): A pharmaceutical composition according to claim 24, further comprising one or more further pharmaceutical agents selected from nicotinic α -7 agonists, PDE4 inhibitors, calcium channel blockers, muscarinic m1 and m2 modulators, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, and cannabinoid modulators